Forty Seven Management Team
6 Team Members
Forty Seven has 6 executives. Forty Seven's current President is Mark A McCamish.
Compare Forty Seven to Competitors
OncoResponse develops therapeutic antibodies for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). It develops cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. The company was founded in 2015 and is based in Seattle, Washington.
ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies. The company develops a molecule that targets the oxidative phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and selects cancer cells. It was founded in 2015 and is based in Houston, Texas.
Immune-Onc Therapeutics is a clinical-stage company that focuses on the development of novel myeloid checkpoint inhibitors in the healthcare and biotechnology industry. The company's main offerings include the development of immunotherapies for cancer, harnessing the body's own immune system to fight against disease, with a particular focus on blood cancers and solid tumors. Immune-Onc primarily sells to the healthcare industry, specifically in the field of cancer treatment. It was founded in 2016 and is based in Palo Alto, California.
Fortis Therapeutics is a company focused on the development of novel, first-in-class therapeutics in the healthcare and biotechnology industry. The company's main offerings include precision therapies that target CD46 proteins in cancer cells, while sparing normal tissues. The company primarily serves the healthcare industry, specifically the oncology sector. It was founded in 2016 and is based in La Jolla, California.
Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.
Epsilogen focuses on the development of immunoglobulin E (IgE) antibodies. The company's main offerings include the development of IgE-based drugs that are designed to treat solid tumors, leveraging the potency, enhanced tumor access, and long tissue half-life of IgE. It primarily serves the oncology sector of the healthcare industry. Epsilogen was formerly known as IGEM Therapeutics. It was founded in 2016 and is based in London, United Kingdom.